Despite substantial progress in tackling the HIV epidemic worldwide in the past two decades, there is one population in which the epidemic continues to grow in countries of all incomes: men who have sex with men (MSM). A six-part Series by THE LANCET, explore the unique aspects of the HIV epidemic in MSM, showing that factors such as the biology of HIV transmission in anal sex and the characteristics of MSM networks, as well as known behavioural factors, are driving the epidemic in this population.

A number of papers are carrying stories about the prospects for an HIV cure - this commentary in The Lancet explains what the Berlin patient has taught us.

The young TB patients at Cape Town'€™s Brooklyn Chest Hospital will be able to cosy up this winter following donations of warm clothes, toys and baby food. By Kim Cloete.

South African HIV Clinicians have welcomed an announcement that the Food and Drug Administration (FDA) in the United States has approved the use of an antiretroviral by sexually active HIV-negative men and women as a method of reducing the risk HIV infection in adults.

People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers.

A new clinical trial in the area of HIV prevention for women is underway in South Africa. It is known as '€œThe Ring Study'€ and it will test the long-term safety and preventive efficacy of an antiretroviral drug, dapivirine, when this is contained in a vaginal ring that releases the drug into the vagina in a sustained manner.

AIDS activists and researchers are at loggerheads over the planned South African trial of a lower dose version of the controversial antiretroviral stavudine, which has in the past been responsible for debilitating side-effects in HIV patients.

The national health department has contracted additional pharmaceutical manufacturers to make up the critical shortage of the antiretroviral tenofovir across the country.

One third of all HIV infected South Africans are accessing antiretroviral therapy (ART), far exceeding the enrolment targets of the country'€™s National Strategic Plan (NSP) for 2007 to 2011.

Activists have sent another letter to Cepheid, the manufacturer of the revolutionary GeneXpert multi-drug resistant TB diagnostic machine, urging them to bring down the price of their products so that more people can access this lifesaving test.

HIV activists and senior doctors have called for an urgent investigation into the continued rollout of a controversial male circumcision device in KwaZulu-Natal.